Canada: The Continuing Saga Of Permissible Deal Protections In Delaware: Standstill / Pill Combo Not Preclusive If The Mechanics Are Right

Following a trilogy of cases1 decided in late 2012 by the Delaware Court of Chancery, dealing with standstill provisions2 in non-disclosure agreements ("NDAs"), the same court on February 25, 2013 denied, in a Memorandum Opinion3 of Vice Chancellor Glasscock, a motion to expedite brought by class action plaintiffs attempting to enjoin the acquisition of BioClinica, Inc. ("BioClinica") by private equity firm JLL Partners, Inc. ("JLL").

While the motion to expedite the complaint to enjoin the merger was based upon (i) an allegation of improper process and (ii) inadequate disclosure claims, the following only addresses the allegation of improper process.

The plaintiffs specifically alleged that the agreement of the Special Committee of BioClinica to a combination of deal protection devices, including a no-shop clause, a top-up feature, matching rights, a termination fee, a poison pill, and the standstill provisions in the NDAs with prospective bidders, impermissibly locked up the merger agreement with JLL and was preclusive to other potential bidders.4

The Court focussed on the joint effect of BioClinica's poison pill and the NDA standstill provisions which restricted potential bidders from engaging in several practices that would enable the bidder to acquire BioClinica.

While the defendants contended that the NDAs did not contain "don't ask, don't waive" restrictions (see footnote 2), the Court cited the plaintiff's motion record to the effect that this was likely to be a contested fact "because the NDA... still limits the circumstances in which [a bidder] can re-enter any bidding process to a tender offer process." The Court continued to cite the plaintiff's motion record arguing that the rights agreement (poison pill) was triggered by a public announcement of an intent to commence a tender or exchange offer for BioClinica, and the plaintiff's assertion that:

"Therefore, it appears the NDAs, in the context of the Rights Agreement, and in the context of the Deal Protection Terms of the Merger Agreement, operate to prevent former prospective purchasers from seeking either publicly or privately to re-enter the bidding process."

It would appear that the plaintiffs were attempting to characterize the issue within the "don't ask, don't waive" line of cases and the Court appeared to agree:

"A deal protection tool that could both (1) relegate a bidder to making a tender offer, without approaching the board of directors, and then (2) trigger the onerous provisions of a poison pill upon the mere announcement of such a tender offer could indeed preclude a bid from any party that had signed such an NDA".

However, after reviewing BioClinica's poison pill, the Court concluded that the pill's harsh efforts were not, in fact, triggered by the mere announcement of the intent to launch a tender offer. This was so because the dilution mechanics and pricing worked as follows: prior to a bidder acquiring over 20% of BioClinica'scommon stock, stockholders only had the right to purchase preferred stock at a price of $16 for 1/1000 of a preferred share, and a 1/1000 interest in a preferred share equated to the value of approximately one common share. Mathematically, this meant that the "right" was an option to acquire common stock worth $7.25 a share for a price of $16 and that "obviously, no rational stockholder would make such a  purchase." Accordingly, substantial dilution was not triggered by the mere public announcement of a tender offer under the rights plan.

The Court went on to conclude that the "teeth of the rights plan are only exposed once a bidder acquires over 20% of the BioClinica's common stock" since only at that point are stockholders given the option to purchase two common shares, at half price, for every one share they hold.

The drafting of these mechanics avoided the "traditional discriminatory impact on the bidding stockholder" since the true trigger was not the announcement of the bid by the bidder but, rather, the acquisition of 20% of the stock, since prior to that point the board has the right to redeem the pill at its option.

The Court relied upon Vice Chancellor Noble's decision in In re Orchid Cellmark Shareholder Litigation5 whereby the Vice Chancellor refused to preliminarily enjoin a merger with a similar set of deal protection devices, on the basis that "the deterrent effects of a poison pill on any serious competing bidder would be minimal" and concluded "the same is true here."

The takeaway here, as is so often the situation in deal protection challenges, would appear to be that drafting and mechanics matter. Provided that stockholders can withdraw their tendered shares from the initial bidder's offer prior to takedown and provided the acquisition agreement contains a fiduciary-out clause permitting the target board to deal with superior offers where the initial bidder has a matching right, the mechanics are in place to allow the auction to continue, thus "ensuring the stockholders receive the highest price available to them." If the target board refuses to redeem the pill in the face of a superior offer, the Court suggested that "the stockholders and the hostile bidder would be free to petition this Court for relief." The Court concluded that, as in Orchid, "a sophisticated buyer could navigate [these] shoals if it wanted to make a serious bid."


1 "In re Celera Corporation Shareholder Litigation, C.A. No. 6304-VCP (Del. Ch. Mar. 23, 2012); In re Complete Genomics, Inc. Shareholder Litigation, C.A. No. 7888-VCL (Del. Ch. Nov. 27, 2012); and In re: Inc. Shareholder Litigation, C.A. No. 7988-CS (Del. Ch. Dec. 17, 2012).

2 Standstill provisions are often included in NDAs which prospective bidders participating in an auction process for a target company are obliged to provide in order to protect the validity of the auction process. The trilogy of cases examined the combination of the provisions in the NDA, which often  include a covenant by the potential bidder not to ask, privately or publicly, the target to release it from its agreement not to bid for the company (often for 18 months), coupled with provisions in the acquisition agreement (a merger agreement or plan of arrangement) whereby the target agrees with the successful bidder not to waive any provisions in the NDA. This combination has come to be known as "don't ask, don't waive" deal protection. The third bench opinion in the trilogy of cases,, decided by Chancellor Strine, appeared to conclude that such a combination, although a "powerful tool", was not per se illegal, and in the right circumstances could be consistent with the target directors' fiduciary duties, but caution was required.

3 In re BioClinica, Inc. Shareholder Litigation, No. 8272-VCG, 2013 WL 673736 (Del. Ch. Feb. 25, 2013).

4 The plaintiffs relied upon Omnicare, Inc. vs. NCS Healthcare, Inc., 818 A.2d 914, 938 (Del. 2003).  Omnicare was a decision by the Delaware Supreme Court which is often cited for the proposition that a target board cannot accede to a demand by a successful bidder for an absolute lock-up that is either preclusive to other bidders or coercive to the stockholders.

5 2011 WL 1938253 (Del. Ch. May 12, 2011).

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
8 Nov 2016, Seminar, Ottawa, Canada

The prospect of an internal investigation raises many thorny issues. This presentation will canvass some of the potential triggering events, and discuss how to structure an investigation, retain forensic assistance and manage the inevitable ethical issues that will arise.

22 Nov 2016, Seminar, Ottawa, Canada

From the boardroom to the shop floor, effective organizations recognize the value of having a diverse workplace. This presentation will explore effective strategies to promote diversity, defeat bias and encourage a broader community outlook.

7 Dec 2016, Seminar, Ottawa, Canada

Staying local but going global presents its challenges. Gowling WLG lawyers offer an international roundtable on doing business in the U.K., France, Germany, China and Russia. This three-hour session will videoconference in lawyers from around the world to discuss business and intellectual property hurdles.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.